Previous 10 | Next 10 |
2023-05-31 13:08:31 ET Roth MKM has started coverage of Terns Pharmaceuticals ( NASDAQ: TERN ) with a buy rating as it sees potential with the company's assets for oncology, nonalcoholic steatohepatitis ( NASH ), and obesity. The firm has a $23 price target (~117% upside bas...
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceutica...
FOSTER CITY, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...
2023-05-16 08:31:18 ET GD Culture Group ( GDC ) +45% f ORM 10-Q | quarterly Report. Phio Pharmaceuticals ( PHIO ) +53% a nnounces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas. The Singing Machine Company ( ...
2023-05-15 12:14:19 ET Terns Pharmaceuticals press release ( NASDAQ: TERN ): Q1 GAAP EPS of $0.01. Revenue of $3.2M (-35.4% Y/Y). For further details see: Terns Pharmaceuticals GAAP EPS of $0.01, revenue of $3.2M
- Top-line data from Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) in NASH expected in third quarter of 2023 - TERN-701 (allosteric BCR-ABL) Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Pha...
FOSTER CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...
2023-05-09 08:19:46 ET Summary I present additional information about my methodology for finding the best stocks. Some of the technical tools I use to make final decisions to buy or sell. The leadership of certain stocks and sectors changes occasionally, and we can take this i...
2023-05-04 03:08:32 ET Summary My journey on the road to finding the best portfolio. My early attempts to find the best stocks in which to invest. My success in finding the best methods. I feel it is about time to publish my latest stock recommendations as I have, I ...
2023-03-30 14:28:14 ET Shares of Terns Pharmaceuticals (NASDAQ: TERN) were up 30.7% for the week Thursday afternoon after being up as much as 37.2% for the week, according to data provided by S&P Global Market Intelligence . The healthcare stock closed at $8.92 last week...
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
Terns Pharmaceuticals Inc. Website:
2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...
2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...